s0122203
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.600
- E2F_TARGETS+0.500
- MYC_TARGETS_V1+0.500
- OXIDATIVE_PHOSPHORYLATION+0.500
- G2M_CHECKPOINT+0.400
- MTORC1_SIGNALING+0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.400
- ADIPOGENESIS+0.300
- DNA_REPAIR+0.300
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.400
- ALLOGRAFT_REJECTION-0.300
- IL6_JAK_STAT3_SIGNALING-0.300
- INFLAMMATORY_RESPONSE-0.300
- INTERFERON_ALPHA_RESPONSE-0.300
- APICAL_JUNCTION-0.200
- APICAL_SURFACE-0.200
- HEDGEHOG_SIGNALING-0.200
- KRAS_SIGNALING_UP-0.200
- UV_RESPONSE_DN-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E9-A1RB-01A-11R-A157-07 | — | C | 0.857 |
| 2 | SRR12696752 | — | — | 0.853 |
| 3 | beb52b13-584a-4227-abe8-9861c3388c14 | — | — | 0.832 |
| 4 | MDT-AP-0322 | Med | Medulloblastoma | 0.831 |
| 5 | TCGA-73-4670-01A-01R-1206-07 | — | cohortA4 | 0.830 |
| 6 | TCGA-BB-A5HY-01A-11R-A28V-07 | — | — | 0.827 |
| 7 | TCGA-DQ-7588-01A-11R-2081-07 | — | — | 0.822 |
| 8 | TCGA-33-4586-01A-01R-1443-07 | — | cohortSQ2 | 0.819 |
| 9 | SRR8942949 | — | — | 0.816 |
| 10 | TCGA-AR-A1AS-01A-11R-A12P-07 | — | B | 0.811 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.300 | Idelalisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |